The organic revenue growth was positively impacted by stock building in primarily
EBIT in the second quarter amounted to
- “In these extraordinary times, our priorities at
Coloplast are clear. We want to keep our employees safe, while continuing to serve our customers. Our customers rely on our help and support, so they can continue to manage their conditions. We have implemented a multitude of new guidelines and safety measures across our company to ensure a safe and stable supply of products for users and healthcare professionals, and I am very proud of the work that is being done by our many teams across the world,” saysColoplast CEOKristian Villumsen and continues: - “Looking at our results, we deliver a solid Q2. Our organic revenue growth continues to be twice the market growth, and we continue to invest in innovation and commercial initiatives to drive future market share gains and raise the standard of care for our users.”
- “The Chronic Care business ex-
China delivered solid underlying performance in Q2. We also saw a large positive impact from stock building in primarilyEurope due to the COVID-19 outbreak. This is expected to gradually reverse once the situation normalises. As communicated in our revised financial guidance on18 March 2020 , the COVID-19 outbreak is also expected to have a material negative impact on the Interventional Urology business and elective procedures in primarily the US. The global outlook for Ostomy Care, Continence Care and Wound &Skin Care remains largely intact.”
In the second quarter of the 2019/20 financial year, organic growth rates by business area were 10% in Ostomy Care, 12% in Continence Care, 3% in Interventional Urology, and 4% in Wound &
The COVID-19 outbreak adversely affected the growth performance in Ostomy Care and Wound Care in
Looking at sales by geography for Q2, the European markets contributed with 9% growth, Other developed markets delivered 11% revenue growth, while Emerging Markets provided a 7% increase. Growth in
COVID-19 outbreak
During the COVID-19 outbreak, the health and safety of the company’s employees and continuity of service to customers continue to be the key priorities.
Coloplast’s global production and distribution sites continue to operate at normal levels and the company is able to fully meet demand.
The company has donated Comfeel products, cash and medical personal protective equipment across several markets to local authorities and NGOs.
Financial guidance for 2019/20
Capital expenditure is now expected to be DKK ~950m vs. ~850m previously. The effective tax rate is still expected to be about ~23%
The company will pay a half-year interim dividend of
CONTACTS
Lina Danstrup
Senior Media Relations Manager, Corporate Communications
+45 49 11 26 07
dklina@coloplast.com
Ellen Bjurgert
Vice President, Investor Relations
+45 49 11 33 76
dkebj@coloplast.com
Financial highlights and key ratios (DKKm) | 2019/20 Q2 | 2018/19 Q2 | Change |
Revenue | 4,823 | 4,401 | 10% |
EBIT | 1,542 | 1,342 | 15% |
EBIT margin | 32% | 30% | |
Profit for the period | 1,067 | 1,021 | 5% |
Sales performance by business area (DKKm) | 2019/20 Q2 | 2018/19 Q2 | Organic growth | Reported growth |
Ostomy Care | 1,920 | 1,742 | 10% | 10% |
Continence Care | 1,776 | 1,584 | 12% | 12% |
Interventional Urology | 507 | 484 | 3% | 5% |
Wound & | 620 | 591 | 4% | 5% |
Revenue | 4,823 | 4,401 | 9% | 10% |
Financial guidance | Guidance for 2019/20 | Guidance for 2019/20 (DKK) |
Sales growth | 4-6% (organic) | 4-6% |
EBIT margin | 30-31% (at constant exchange rates) | 30-31% |
Capital expenditure | - | ~950m |
Tax rate | - | ~23% |
Attachment
Coloplast Q2 2019_2020_PM_ENG
© OMX, source